Endoscopic transoral outlet reduction induces enterohormonal changes in patients with weight regain after Roux-en-Y gastric bypass

Abstract

Background and study aims Transoral outlet reduction (TORe) has long been employed in treating weight regain after Roux-en-Y gastric bypass. However, its impact on gut hormones and their relationship with weight loss remains unknown.

Patients and methods This was a substudy of a previous randomized clinical trial. Adults with significant weight regain and dilated gastrojejunostomy underwent TORe with argon plasma coagulation (APC) alone or APC plus endoscopic suturing (APC-suture). Serum levels of ghrelin, GLP-1, and PYY were assessed at fasting, 30, 60, 90, and 120 minutes after a standardized liquid meal. Results were compared according to allocation group, clinical success, and history of cholecystectomy.

Results Thirty-six patients (19 APC vs. 17 APC-suture) were enrolled. There were no significant baseline differences between groups. In all analyses, the typical postprandial decrease in ghrelin levels was delayed by 30 minutes, but no other changes were noted. GLP-1 levels significantly decreased at 12 months in both allocation groups. Similar findings were noted after dividing groups according to the history of cholecystectomy and clinical success. The APC cohort presented an increase in PYY levels at 90 minutes, while the APC-suture group did not. Naïve patients had significantly lower PYY levels at baseline (P = 0.01) compared with cholecystectomized individuals. This latter group experienced a significant increase in area under the curve (AUC) for PYY levels, while naïve patients did not, leading to a higher AUC at 12 months (P = 0.0001).

Conclusions TORe interferes with the dynamics of gut hormones. APC triggers a more pronounced enteroendocrine response than APC-suture, especially in cholecystectomized patients.

Keywords

Endoscopy Upper GI Tract - GI surgery

Publikationsverlauf

Eingereicht: 11. Mai 2023

Angenommen nach Revision: 16. April 2024

Accepted Manuscript online:
23. April 2024

Artikel online veröffentlicht:
29. Mai 2024

• References

• 1 Angrisani L, Santonicola A, Iovino P. et al. IFSO Worldwide Survey 2016: Primary, Endoluminal, and Revisional Procedures. Obes Surg 2018; 28: 3783-3794 DOI: 10.1007/s11695-018-3450-2. (PMID: 30121858)
• 2 American Society for Metabolic and Bariatric Surgery. Estimate of bariatric surgery numbers, 2011–2019. https://asmbs.org/resources/estimate-of-bariatric-surgery-numbers
• 3 Cooper TC, Simmons EB, Webb K. et al. Trends in weight regain following roux-en-y gastric bypass (RYGB) bariatric surgery. Obes Surg 2015; 25: 1474-1481 DOI: 10.1007/s11695-014-1560-z. (PMID: 25595383)
• 4 Jirapinyo P, Abu Dayyeh BK, Thompson CC. Weight regain after Roux-en-Y gastric bypass has a large negative impact on the Bariatric Quality of Life Index. BMJ Open Gastroenterol 2017; 4: e000153 DOI: 10.1136/bmjgast-2017-000153. (PMID: 28944069)
• 5 Thompson CC, Chand B, Chen YK. et al. Endoscopic suturing for transoral outlet reduction increases weight loss after Roux-en-Y gastric bypass surgery. Gastroenterology 2013; 145: 129-137.e3
• 6 Brunaldi VO, Jirapinyo P, de Moura DTH. et al. Endoscopic treatment of weight regain following Roux-en-Y gastric bypass: A systematic review and meta-analysis. Obes Surg 2017; 28: 1-11
• 7 Baptista A, Hourneaux De Moura DT, Jirapinyo P. et al. Efficacy of the cardiac septal occluder in the treatment of post-bariatric surgery leaks and fistulas. Gastrointest Endosc 2019; 89: 671-679.e1
• 8 Barrichello S, Galvao Neto MDP, Ferreira de Souza T. et al. Increased gastric retention capacity, assessed by scintigraphy, after APC treatment of dilated gastrojejunal anastomosis. GE Portuguese J Gastroenterol 2018; 25: 327-330
• 9 Riccioppo D, Santo MA, Rocha M. et al. Small-volume, fast-emptying gastric pouch leads to better long-term weight loss and food tolerance after Roux-en-Y gastric bypass. Obes Surg 2018; 28: 693-701 DOI: 10.1007/s11695-017-2922-0. (PMID: 28913642)
• 10 Santo MA, Riccioppo D, Pajecki D. et al. Weight regain after gastric bypass: Influence of gut hormones. Obes Surg 2016; 26: 919-925 DOI: 10.1007/s11695-015-1908-z. (PMID: 26450709)
• 11 Meek CL, Lewis HB, Reimann F. et al. The effect of bariatric surgery on gastrointestinal and pancreatic peptide hormones. Peptides 2016; 77: 28-37 DOI: 10.1016/j.peptides.2015.08.013. (PMID: 26344355)
• 12 Brunaldi VO, Farias GFA, de Rezende DT. et al. Argon plasma coagulation alone versus argon plasma coagulation plus full-thickness endoscopic suturing to treat weight regain after Roux-en-Y gastric bypass: a prospective randomized trial (with videos). Gastrointest Endosc 2020; 92: 97-107.e5
• 13 Lan T, Morgan DA, Rahmouni K. et al. FGF19, FGF21, and an FGFR1/β-Klotho-Activating antibody act on the nervous system to regulate body weight and glycemia. Cell Metab 2017; 26: 709-718.e3
• 14 Babaknejad N, Nayeri H, Hemmati R. et al. An overview of FGF19 and FGF21: The therapeutic role in the treatment of the metabolic disorders and obesity. Horm Metab Res 2018; 50: 441-452 DOI: 10.1055/a-0623-2909. (PMID: 29883971)
• 15 Fernandes G, Santo MA, Crespo A de FCB. et al. Early glycemic control and incretin improvement after gastric bypass: the role of oral and gastrostomy route. Surg Obes Relat Dis 2019; 15: 595-601 DOI: 10.1016/j.soard.2019.01.013. (PMID: 30803884)
• 16 Jaruvongvanich V, Vantanasiri K, Laoveeravat P. et al. Endoscopic full-thickness suturing plus argon plasma mucosal coagulation versus argon plasma mucosal coagulation alone for weight regain after gastric bypass: a systematic review and meta-analysis. Gastrointest Endosc 2020; 92: 1164-1175.e6
• 17 Cummings DE, Weigle DS, Frayo RS. et al. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med 2002; 346: 1623-1630 DOI: 10.1056/NEJMoa012908. (PMID: 12023994)
• 18 Stengel A, Taché Y. Regulation of food intake: the gastric X/A-like endocrine cell in the spotlight. Curr Gastroenterol Rep 2009; 11: 448-454 DOI: 10.1007/s11894-009-0069-4. (PMID: 19903420)
• 19 De Silva A, Bloom SR. Gut hormones and appetite control: A focus on PYY and GLP-1 as therapeutic targets in obesity. Gut Liver 2012; 6: 10-20 DOI: 10.5009/gnl.2012.6.1.10. (PMID: 22375166)
• 20 Wilding JPH, Batterham RL, Calanna S. et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med 2021; 384: 989-1002 DOI: 10.1056/NEJMoa2032183. (PMID: 33567185)
• 21 Egerod KL, Engelstoft MS, Grunddal KV. et al. A major lineage of enteroendocrine cells coexpress CCK, secretin, GIP, GLP-1, PYY, and neurotensin but not somatostatin. Endocrinology 2012; 153: 5782-5795 DOI: 10.1210/en.2012-1595. (PMID: 23064014)
• 22 Hutch CR, Sandoval D. The role of GLP-1 in the metabolic success of bariatric surgery. Endocrinology 2017; 158: 4139-4151 DOI: 10.1210/en.2017-00564. (PMID: 29040429)
• 23 Svane MS, Jørgensen NB, Bojsen-Møller KN. et al. Peptide YY and glucagon-like peptide-1 contribute to decreased food intake after Roux-en-Y gastric bypass surgery. Int J Obes (Lond) 2016; 40: 1699-1706 DOI: 10.1038/ijo.2016.121. (PMID: 27434221)
• 24 Dirksen C, Damgaard M, Bojsen-Møller KN. et al. Fast pouch emptying, delayed small intestinal transit, and exaggerated gut hormone responses after Roux-en-Y gastric bypass. Neurogastroenterol Motil 2013; 25: 346-e255 DOI: 10.1111/nmo.12087. (PMID: 23360316)
• 25 Mulla CM, Goldfine AB, Dreyfuss JM. et al. Plasma FGF-19 levels are increased in patients with post-bariatric hypoglycemia. Obes Surg 2019; 29: 2092-2099
• 26 Rhee NA, Wahlgren CD, Pedersen J. et al. Effect of Roux-en-Y gastric bypass on the distribution and hormone expression of small-intestinal enteroendocrine cells in obese patients with type 2 diabetes. Diabetologia 2015; 58: 2254-2258
• 27 Wronska E, Polkowski M, Orlowska J. et al. Argon plasma coagulation for Barrett’s esophagus with low-grade dysplasia: a randomized trial with long-term follow-up on the impact of power setting and proton pump inhibitor dose. Endoscopy 2021; 53: 123-132
• 28 Schölvinck DW, Künzli HT, Kestens C. et al. Treatment of Barrett’s esophagus with a novel focal cryoablation device: a safety and feasibility study. Endoscopy 2015; 47: 1106-1112
• 29 Mingrone G, van Baar AC, Devière J. et al. Safety and efficacy of hydrothermal duodenal mucosal resurfacing in patients with type 2 diabetes: the randomised, double-blind, sham-controlled, multicentre REVITA-2 feasibility trial. Gut 2021; 71: 254-264
• 30 Hourneaux de Moura DT, Hathorn KE, Thompson CC. You just got burned! What is wrong with this gastric pouch?. Gastroenterology 2019; 156: 2139-2141 DOI: 10.1053/j.gastro.2019.01.255. (PMID: 30716322)